Comparative Pharmacology
Head-to-head clinical analysis: R P MYCIN versus TAO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: R P MYCIN versus TAO.
R-P MYCIN vs TAO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
Troleandomycin (TAO) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
250-500 mg orally every 6 hours or 500 mg intravenously every 6 hours. For severe infections, up to 500 mg every 6 hours IV.
None Documented
None Documented
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Terminal elimination half-life of 12-24 hours in adults; may be prolonged in hepatic impairment (up to 40-60 hours) and in neonates (2-5 days).
Renal (60-80% unchanged), biliary/fecal (15-20%).
Primarily hepatic metabolism with <10% excreted unchanged in urine; approximately 30% excreted in feces via bile.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic